IntegenX Leadership

Dr. Dennis Harris is a co-founder of IntegenX and is an experienced executive who has spent the majority of his career developing and implementing business strategies for life science companies to maximize their research and development efforts and to enhance their ability to bring innovation to customers. In his various roles, he has initiated and led successful portfolio acquisitions and negotiated technology collaborations. Prior to IntegenX, he served as Chief Scientific Officer at Millipore since 2006. He was Vice President and Chief Scientific Officer at Serologicals Corporation from 2004 to 2006 and Executive Vice President of Research and Development at Vitra Bioscience from 2002 to 2003. He served as Senior Vice President at Aclara Biosciences, Inc., a developer of microfluidics and gene and protein analysis technologies. Prior to Aclara, he held positions of increasing responsibility at Amersham Pharmacia Biotech (now part of GE Healthcare) including Vice President of Research and Development. Dr. Harris has extensive background in DNA sequencing and laboratory automation systems. Dr. Harris currently serves on the board of directors for IntegenX, and also serves on the board of directors for Biolog, Inc.. Dr. Harris earned his B.SC. Hons. in Biochemistry and Ph.D. from the University of Sussex, England. He has authored 17 papers.

Dr. Dennis Harris is a co-founder of IntegenX and is an experienced executive who has spent the majority of his career developing and implementing business strategies for life science companies to maximize their research and development efforts and to enhance their ability to bring innovation to customers. In his various roles, he has initiated and led successful portfolio acquisitions and negotiated technology collaborations. Prior to IntegenX, he served as Chief Scientific Officer at Millipore since 2006. He was Vice President and Chief Scientific Officer at Serologicals Corporation from 2004 to 2006 and Executive Vice President of Research and Development at Vitra Bioscience from 2002 to 2003. He served as Senior Vice President at Aclara Biosciences, Inc., a developer of microfluidics and gene and protein analysis technologies. Prior to Aclara, he held positions of increasing responsibility at Amersham Pharmacia Biotech (now part of GE Healthcare) including Vice President of Research and Development. Dr. Harris has extensive background in DNA sequencing and laboratory automation systems. Dr. Harris currently serves on the board of directors for IntegenX, and also serves on the board of directors for Biolog, Inc.. Dr. Harris earned his B.SC. Hons. in Biochemistry and Ph.D. from the University of Sussex, England. He has authored 17 papers.

Dr. Dennis Harris is a co-founder of IntegenX and is an experienced executive who has spent the majority of his career developing and implementing business strategies for life science companies to maximize their research and development efforts and to enhance their ability to bring innovation to customers. In his various roles, he has initiated and led successful portfolio acquisitions and negotiated technology collaborations. Prior to IntegenX, he served as Chief Scientific Officer at Millipore since 2006. He was Vice President and Chief Scientific Officer at Serologicals Corporation from 2004 to 2006 and Executive Vice President of Research and Development at Vitra Bioscience from 2002 to 2003. He served as Senior Vice President at Aclara Biosciences, Inc., a developer of microfluidics and gene and protein analysis technologies. Prior to Aclara, he held positions of increasing responsibility at Amersham Pharmacia Biotech (now part of GE Healthcare) including Vice President of Research and Development. Dr. Harris has extensive background in DNA sequencing and laboratory automation systems. Dr. Harris currently serves on the board of directors for IntegenX, and also serves on the board of directors for Biolog, Inc.. Dr. Harris earned his B.SC. Hons. in Biochemistry and Ph.D. from the University of Sussex, England. He has authored 17 papers.